Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2012: Volume 17/ Issue 37 Article 7
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 17, Issue 37, 13 September 2012
News
Updated version of ECDC guidance on human papillomavirus vaccines in Europe available
  1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Citation style for this article: Eurosurveillance editorial team. Updated version of ECDC guidance on human papillomavirus vaccines in Europe available. Euro Surveill. 2012;17(37):pii=20274. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20274

The European Centre for Disease Prevention and Control (ECDC) published an update to its 2008 guidance on human papillomavirus (HPV) vaccines in Europe on 5 September 2012 [1]. The update follows the introduction of vaccination programmes in 19 European countries and new evidence from research studies over the past four years.

Randomised trials and observations from the field have demonstrated good safety profiles and efficacy against cervical cancer precursors for the vaccines. Despite this, and although most of these countries are providing the vaccine for free, vaccination rates are lower than expected.
The vaccination rates for those meeting the prescribed schedule of three doses in six months range from 17% to 84% for the reporting countries. Portugal (84%), the United Kingdom (80%) and Denmark (79%) were at the top of that range. Separate reports suggest that Sweden’s vaccination coverage rate is also around 80% of their target group. The update considers among the deterring factors the high cost of the vaccines and the regime of three doses in six months.

Since the vaccine was authorised, the inclusion of HPV for boys in vaccination programmes is regularly debated. The ECDC guidance document recommends that public health initiatives should continue to focus on vaccinating girls. Routine HPV vaccination should target girls aged 10-14 years before the onset of sexual activity and should be administered in three doses within six months.

The update points to evidence that alternative vaccination schedules are not less effective than the currently recommended protocol of three doses. Further research is needed to confirm this but could have a great impact on costs and strategies for HPV vaccination programmes. The update does not recommend changing the current vaccination schedule at this point in time.


References

  1. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in EU countries – an update. Stockholm: ECDC; 2012. Available from: www.ecdc.europa.eu/en/publications/Publications/20120905_GUI_HPV_vaccine_update.pdf


Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.